Neuronal Ceroid Lipofuscinosis Type 2 Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Neuronal Ceroid Lipofuscinosis Type 2
Neuronal Ceroid Lipofuscinosis type 2 (CLN2 disease) is a rare, progressive neurodegenerative disorder primarily affecting children, leading to severe developmental regression. While specialized treatments are available to slow its progression, the financial burden can be immense. TheDrugClub offers a crucial solution, helping families significantly reduce the cost of essential prescription medications for CLN2 management.
Neuronal Ceroid Lipofuscinosis type 2, often referred to as CLN2 disease or Classic Late Infantile Batten Disease, is a devastating genetic disorder. It's one of several forms of lysosomal storage diseases, characterized by the body's inability to produce enough of a specific enzyme, tripeptidyl peptidase 1 (TPP1). Without sufficient TPP1, waste products called lipofuscins accumulate in the cells, particularly in the brain and nervous system, leading to widespread damage.
Symptoms typically begin between two and four years of age, starting with recurrent seizures and developmental delays. As the disease progresses, children experience a rapid decline in motor skills, loss of speech, vision impairment, and severe cognitive regression. Unfortunately, CLN2 is a progressive and ultimately fatal condition, with most affected children not surviving into their teenage years.
While there is currently no cure for CLN2 disease, significant advancements have been made in treatment options aimed at slowing its progression and managing symptoms. The primary treatment is enzyme replacement therapy (ERT) using cerliponase alfa (Brineura), which is administered directly into the brain via an implanted device. This specialized medication works by replacing the missing TPP1 enzyme, helping to clear the toxic waste products. However, Brineura is an incredibly expensive medication, often costing hundreds of thousands of dollars annually. Beyond ERT, symptomatic treatments are vital, including various anti-se
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.